Cormorant Asset Management, LP Infla Rx N.V. Transaction History

Cormorant Asset Management, LP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2019 Feb 14, 2020	SELL	$2.2 - $4.54 $660,000 - $1.36 Million	-300,000 Closed	0 $0
Q3 2019 Nov 14, 2019	SELL	$2.47 - $3.51 $2.96 Million - $4.21 Million	-1,200,000 Reduced 80.0%	300,000 $741,000
Q2 2019 Aug 14, 2019	SELL	$3.06 - $51.61 $3.34 Million - $56.3 Million	-1,090,000 Reduced 42.08%	1,500,000 $4.74 Million
Q1 2019 May 15, 2019	BUY	$31.16 - $48.62 $34.7 Million - $54.2 Million	1,114,860 Added 75.58%	2,590,000 $97.9 Million
Q4 2018 Feb 14, 2019	BUY	$23.33 - $36.37 $3.12 Million - $4.86 Million	133,600 Added 9.96%	1,475,140 $53.7 Million

Q3 2018 Nov 14, 2018	SELL	$29.34 - $35.0 $4.28 Million - $5.1 Million	-145,725 Reduced 9.8%	1,341,540 $46 Million
Q2 2018 Aug 14, 2018	BUY	$27.33 - $41.46 $2.41 Million - $3.66 Million	88,235 Added 6.31%	1,487,265 $48 Million
Q1 2018 May 15, 2018	SELL	$20.21 - $32.0 $791,767 - $1.25 Million	-39,177 Reduced 2.72%	1,399,030 $40.3 Million
Q4 2017 Feb 14, 2018	BUY	$14.55 - $23.99 $20.9 Million - $34.5 Million	1,438,207	1,438,207 $30.1 Million

13.8M

12.9K

Ticker IFRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 44,203,800
Market Cap $72.5M
Description
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a nov...

Get notified when there are updates to the investment portfolio of Cormorant Asset Management, LP, based on Form 13F filings with the SEC.

Stay updated on Cormorant Asset Management, LP with notifications on news.